Dr Jaime Schneider, MD, PhD from Massachusetts General Hospital Cancer Center comments on the expanded use of targeted treatments and molecular testing in lung cancer, beyond EGFR mutations: Availability of treatments for an expanding range of oncogenic driver mutations necessitates broad molecular testing at time of diagnosis for patients with advanced NSCLC.
